We hope that this combination
will allow us to see more complete responses in patients with difficult to treat diseases, like
the one seen in the Phase 1A study that has resulted in complete tumour eradication for
more than 15 months now.”
Combination therapy is the way to go in this field, and this NK platform can be combined in endless ways.
Heaps of shots on goal coming up, and if just one hits the back of the net, we are of and running.
This stock is ridiculously cheap with the platforms it has and the amount of combinations it will be taking to clinic.
I certainly will be buying more here when funds come available.
- Forums
- ASX - By Stock
- Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib
CHM
chimeric therapeutics limited
Add to My Watchlist
25.0%
!
0.5¢

We hope that this combination will allow us to see more complete...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $10.07M |
Open | High | Low | Value | Volume |
0.4¢ | 0.5¢ | 0.4¢ | $11.08K | 2.623M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 4706271 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 14960701 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 4706271 | 0.004 |
42 | 27903271 | 0.003 |
15 | 13950505 | 0.002 |
10 | 50600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 14960701 | 24 |
0.006 | 13343479 | 16 |
0.007 | 3200000 | 3 |
0.008 | 8542434 | 6 |
0.009 | 2327672 | 4 |
Last trade - 11.14am 23/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |